Compare Recursion Pharmaceuticals Inc (RXRX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Xcel Energy Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Xcel Energy Inc trades at $78.62 (market cap $49.11B). The key difference: Xcel Energy Inc is far larger — about 32.1× Recursion Pharmaceuticals Inc's market cap, and Xcel Energy Inc pays a 3.01% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | XEL | |
|---|---|---|
Market Cap | $1.53B | $49.11B |
Sector | Health | Utilities |
52-Week High | $6.79 | $83.91 |
52-Week Low | $2.84 | $71.14 |
Enterprise Value | $946.50M | $86.55B |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
XEL trades at $78.72, down 0.06% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $14.67B in 2025, with a net income margin of 14.14%. Analyst consensus is bullish with a $94.50 price target, and the company maintains a steady dividend, with a recent payout declared for July 2026.
The outlook for XEL is supported by strong analyst buy ratings and a significant capital expenditure plan targeting growth, but risks include regulatory pushback and high debt levels. The stock's current valuation near historical highs requires monitoring of earnings delivery against expectations, particularly the upcoming Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
